Ray Dalio's DXCM Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 149,264 shares of DexCom, Inc. (DXCM) worth $9.91 M, representing 0.04% of the portfolio. First purchased in 2020-Q3, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in DXCM, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2021, adding 275,520 shares. Largest reduction occurred in Q4 2024, reducing 221,691 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's DexCom (DXCM) Holding Value Over Time
Track share changes against reported price movement
Quarterly DexCom (DXCM) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +28,769 | Add 23.88% | 149,264 | $66.37 |
| Q3 2025 | -133,316 | Reduce 52.53% | 120,495 | $67.29 |
| Q2 2025 | +182,515 | Add 256.00% | 253,811 | $87.29 |
| Q1 2025 | -26,642 | Reduce 27.20% | 71,296 | $68.29 |
| Q4 2024 | -221,691 | Reduce 69.36% | 97,938 | $77.77 |
| Q3 2024 | -27,695 | Reduce 7.97% | 319,629 | $67.04 |
| Q2 2024 | -23,540 | Reduce 6.35% | 347,324 | $113.38 |
| Q1 2024 | -62,291 | Reduce 14.38% | 370,864 | $138.70 |
| Q4 2023 | -168,208 | Reduce 27.97% | 433,155 | $124.09 |
| Q3 2023 | +183,141 | Add 43.79% | 601,363 | $93.30 |
| Q2 2023 | -37,149 | Reduce 8.16% | 418,222 | $128.51 |
| Q1 2023 | +23,847 | Add 5.53% | 455,371 | $116.18 |
| Q4 2022 | -191,759 | Reduce 30.77% | 431,524 | $113.24 |
| Q3 2022 | -9,771 | Reduce 1.54% | 623,283 | $80.54 |
| Q2 2022 | +52,090 | Add 8.97% | 633,054 | $74.53 |
| Q1 2022 | +154,828 | Add 36.33% | 580,964 | $127.90 |
| Q4 2021 | +49,124 | Add 13.03% | 426,136 | $134.24 |
| Q3 2021 | -44,636 | Reduce 10.59% | 377,012 | $136.71 |
| Q2 2021 | +275,520 | Add 188.55% | 421,648 | $106.75 |
| Q1 2021 | +16,032 | Add 12.32% | 146,128 | $89.85 |
| Q4 2020 | +60,420 | Add 86.72% | 130,096 | $92.43 |
| Q3 2020 | +69,676 | New Buy | 69,676 | $103.06 |
Ray Dalio's DexCom Investment FAQs
Ray Dalio first purchased DexCom, Inc. (DXCM) in Q3 2020, acquiring 69,676 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held DexCom, Inc. (DXCM) for 22 quarters since Q3 2020.
Ray Dalio's largest addition to DexCom, Inc. (DXCM) was in Q2 2021, adding 421,648 shares worth $45.01 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 149,264 shares of DexCom, Inc. (DXCM), valued at approximately $9.91 M.
As of the Q4 2025 filing, DexCom, Inc. (DXCM) represents approximately 0.04% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in DexCom, Inc. (DXCM) was 633,054 shares, as reported at the end of Q2 2022.